AllDocs -> cancers

Vaccine 24 (2006) 3420–3425 A non-invasive QPCR method monitoring DNA based therapy of bladder cancer patients Suhail Ayesh a , b , * , Rasha Abu-Lail a , Abraham Hochberg a a The Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel b Molecular Genetics Laboratory, Makassed Islamic Charitable Hospital, Jerusalem, Israel Received 8 November 2005; received in revised form 25 January 2006; accepted 8 February 2006 Available online 3 March 2006 Abstract Real-time PCR technology is highly advantageous for gene studies based on the genetic nature of the transferred material. Urine and blood samples were collected before and after treatment. Treatment of bladder carcinoma patients with plasmid constructs expressing the diphtheria toxin ...

M. D. ANDERSON CANCER CENTER BLADDER CANCER TISSUE BANK Specimen Request Form (Page 1 of 5) Date of request: Date needed: Investigator: Email: Department: Phone: Beeper: Fax: Collaborators Department Contact Person Phone: Beeper: Location: Title of Project: Objectives of Project: The tissue requested will be used for (please provide brief description to aid in the selection of samples) : Source of Funding NIH ACS DOD None Other: (specify): Non-NIH peer reviewed Non-peer reviewed The results obtained from the study of the requested tissue samples will: a) Only be correlated with the grade and stage: Yes No Other b) Will require patients’ identity: Yes No Other Do you have institutional approval for this project: ...

BLADDER CANCER SUPPORT GROUP Presented by: University of Michigan Comprehensive Cancer Center and The Department of Urology Date: Sunday, September 10, 2006 Place: University of Michigan Hospital 2 nd floor in Main Hospital, Room 2C108 Speaker: Diane Zipursky Quale, President Bladder Cancer Advocacy Network (BCAN) Topic: Working Together to Increase Public Awareness of Bladder Cancer —You Can Make a Difference Time: 1:00-2:30 P.M. Directions: Main Hospital, RM 2C108 Second Floor across from Cashier’s Window All bladder cancer survivors and their families/significant others are invited. If you know anyone who may have an interest in this meeting, they are also invited to attend. For further information, please contact: Nancy Rodriguez-Galano or Phil Rupp, University of Michigan ...

bladder cancer w h a t y o u s h o u l d k n o w bladder [ blad·der ] Any of various distensible membranous sacs, such as the urinary bladder or the swim bladder , that serve as receptacles for fluid or gas. [ bottom line ] Bladder cancer is the most common cancer of the urinary tract. Cigarette smoking is a well established risk factor for bladder cancer . Increased risks are associated with occupational exposure because of carcinogens in the work place. Incidence of bladder cancer increases with age. Bladder cancer is 2-3 times more common in men . The disease is more prevalent in Whites than African Americans and Hispanics. From 1998-2002, a yearly average of 650 Oklahomans developed bladder cancer . Overall, the Oklahoma bladder cancer rate of 18.2 was less than the national bladder cancer rate of 22.1 per 100,000 people. [ risk factors ...

D A N I S H M E D I C A L B U L L E T I N VO L . 53 NO . 2/ M A Y 2006 223 ABSTRACT OF PhD DISSERTATION Genome-wide gene expression profiling of early bladder cancer , and functional characterization of target genes, using microarrays Mads Aaboe Jensen, MSc The PhD dissertation was accepted by the Faculty of Health Sciences of the University of Aarhus, and defended on March 24, 2006. Official opponents: Francisco X. Real, Spain, Hans Skovgaard Poulsen, and Niels Gregersen. Tutor: Torben F. Ørntoft. Correspondence: Mads Aaboe Jensen, Horsensgade 6, 3. t.v., 8000 Aarhus C, Denmark. E-mail: mads.aaboe@ki.au.dk Dan Med Bull 2006;53:223 ABSTRACT This PhD dissertation consists of four articles and one submitted manuscript. The studies have been conducted at the Molecular Diagnostic Laboratory, ...

Guidelines for Management of Bladder Cancer Version History: Version Summary of change Date Issued Draft 0.1 First Development of guideline . Draft 0.3 Following discussion at NSSG 9.11.05 Draft 0.4 Following Discussion with Dr Tudway and Dr Guest. 16.12.05 Draft 0.5 Following TD and PG comments 06.01.06 Draft .06 With Prof Nick James Comments 10.01.06 Draft 0.7 Following NSSG 11.01.06 Draft 0.8 Final Draft for consideration by the NSSGs for Urology, Cellular Pathology and Radiology 24.01.06 Draft 0.9 For consideration by the clinical governance committee 31.01.06 Scope of the Guideline This Guidance has been produced to support the following: • The management of patients presenting with symptoms suspicious of Bladder Cancer . • The management ...

Final Guidelines for Management of Testicular Cancer Version History: Version Summary of change Date Issued Draft 0.1 First Development of guideline with consultation between Alan Ferguson, Paul Hutton and Mike Wallace Draft 0.2 Following discussion between Lara Barnish and Paul Hutton 13.12.05 Draft 0.3 With Peter Guest Comments 06.01.06 Draft 0.4 Following mtg LB, PH and AF 16.01.06 Draft 0.5 Following consultation (inc. Mike Cullen comments). For circulation to the NSSGs for urology, cellular pathology, and radiology 24.01.06 Draft 0.6 With genetics addition for final approval by NSSGs prior to CG submission 07.02.06 Draft 0.7 For submission to Clinical Governance 13.02.06 1 Scope of the Guideline This Guidance has been produced to support ...

NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Bladder Cancer (3H) 1 National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Bladder Cancer Herbert A. Fritsche, 1 H. Barton Grossman, 2 Seth P Lerner 3 , Ihor Sawczuk 4 1 Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; 2 Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; 3 Department of Urology, Baylor College of Medicine, Houston, Texas, USA; 4 Department of Urology, Hackensack University Medical Center, Hackensack, New Jersey, USA. *Sub-Committee Chair , to whom all comments should be addressed via e-mail to hfritsche@mdanderson.org ...

Mortality from Bladder Cancer Across Bedfordshire and Hertfordshire (SMR) 2002-2004, All Ages, by Primary Care Trust (PCT) Notes Mortality from bladder cancer (ICD10 C67) Indirectly standardised ratios (SMR) All ages 2002-04 (Pooled) England 2002-04 = 100 (Standard rates are England annual age-specific rates 2002-04) Data are based on the original underlying cause of death. Data are based on the latest revisions of ONS population estimates for the respective years, current as at 20 December 2005. Highlights Bladder cancer mortality ratios at PCT level in Bedfordshire and Hertfordshire were not significantly different from England. The highest mortality ratios were in Bedfordshire Heartlands PCT and North Hertfordshire and Stevenage PCT. For More Information Please Contact David Edwards, Public Health Intelligence Epidemiologist (david.edwards@phi-bedsherts.nhs.uk) ...

Computers in Biology and Medicine 36 (2006) 634–655 www.intl.elsevierhealth.com/journals/cobm Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment Shital C. Shah a , Andrew Kusiak a , * , Michael A. O’Donnell b a Intelligent Systems Laboratory, MIE, 3131 Seamans Center, The University of Iowa, Iowa City, IA 52242-1527, USA b Department of Urology, University of Iowa Hospital and Clinics, IA, USA Received 28 January 2005; accepted 4 March 2005 Abstract Bladder cancer is the fifth most common malignant disease in the United States with an annual incidence of around 63,210 new cases and 13,180 deaths. The cost for providing care for patients with bladder cancer disease is high. Bladder cancer treatment options such as immunotherapy, chemotherapy, radiation therapy, transurethral ...

May 3, 2006 MZT Matritech, Inc. Henry McCusker 617.236.6396 hwm@scimitarequity.com Please read the important Disclosures Section At the end of this review Detecting Bladder Cancer Tumors Conventional Methods Miss Ranking: “BUY” Price at 5/02/06 : $1.23 52 Week Range : $1.56 - $0.52 New Price Target: $2.50 - $2.75 Market Capitalization: $64.91 m Enterprise Value: $65.75 m Shares Outstanding: 52.78 m Fiscal Year End: Dec Exchange: AMEX Building on momentum The clinical performance of MZT’s NMP22® BladderChek® Test, the point-of-care urine test, in detecting occult bladder cancers was recently presented at the 21st Annual Congress of the European Association of Urology (EAU) in Paris. The NMP22 BladderChek Test was reported ...

THE MANY FACES OF BLADDER CANCER 2005 ANNUAL REPORT 330 NEVADA STREET, NEWTON, MASSACHUSETTS 02460 USA | PHONE: 617-928-0820, 800-320-2521 | FAX: 617-928-0821 | WWW.MATRITECH.COM Page 2 Matritech is revolutionizing the diagnosis of bladder cancer and helping to save lives. Adding theNMP22 ® BladderChek ® Test to cystoscopy significantly increases the detection of cancer , up to 99%–even finding life threatening cancers missed by the cystoscope. With more than one million NMP22 BladderChek Tests sold, it is becoming standard of care in the management of bladder cancer . C O R P O R A T E I N F O R M A T I O N CORPORATE OFFICERS STEPHEN D. CHUBB CHAIRMAN AND CHIEF EXECUTIVE OFFICER ...

AMERICAN JOURNAL OF INDUSTRIAL MEDICINE 49:175–186 (2006) Bladder Cancer Risk in Sales Workers: Artefact or Cause for Concern? Andrea ’t Mannetje, PhD 1 Ã and Neil Pearce, DSc 1,2 Background A large number of epidemiological studies have reported positive associations between bladder cancer and sales occupations. We investigated whether these findings are likely to be due to chance, confounding or publication bias, or may involve causal associations. Methods Studies reporting bladder cancer risk-estimates for sales occupations were reviewed. Using meta-analyses we assessed heterogeneity and publication bias, and derived summary estimates. Results Eighteen publicationswere identified, reporting 85 risk-estimates for sales-work. Meta-estimates were elevated for men (odds ratio (OR) 1.11, 95% confidence interval (CI) 1.01–1.21) and women ...

Survival Drops When Bladder Cancer Surgery Is Deferred By Neil Osterweil, MedPage Today Staff Writer Reviewed by Zalman S. Agus, MD; Emeritus Professor at the University of Pennsylvania School of Medicine. March 28, 2006 ANN ARBOR, Mich., March 28, 2006 - In patients with muscle invasive bladder cancer , surgery delayed is survival denied, reported researchers here. Among 214 patients with muscle-invasive bladder cancer , those who had surgery within three months of diagnosis had a 51% survival rate at three years, compared with only 38% for those whose surgery was delayed past three months, reported Cheryl Lee, M.D., and colleagues of the University of Michigan's Comprehensive Cancer Center. The most common reason for delaying surgery was because of physician scheduling problems, they reported in the April issue of the Journal of Urology. Only a few patients took ...

Antitumor Effect of Nutrient Synergy on Human Bladder Cancer Cell Lines T-24 M.W. Roomi, V. Ivanov, A. Niedzwiecki, M. Rath Matthias Rath Research., Cancer Research Division, Santa Clara, CA 95050 Presented at: Mayo Clinic Conference on Dietary Factors and Cancer Prevention, Rochester, MN, September 23-25, 2004. Published in: Dietary Factors and Cancer Prevention: Current Premises and Future Promises, Abstract #25, pg 51. Abstract Background: Bladder cancer , the fourth most frequently diagnosed cancer in men and the tenth in women, develops mainly in older adults. If treated while in situ, prognosis is excellent. Once the cells have metastasized, prognosis is poor. We investigated the synergistic effect of a unique nutrient formulation (NM) containing lysine, proline, arginine, ascorbic acid, and epigallocatechin gallate on human bladder cancer cells T-24 by ...

Lisette Hilton UT CORRESPONDENT Rochester, NY— A point-of-care assay that measures the nuclear matrix protein NMP22 in urine significantly improves detection of recurrent bladder cancer when used with cys- toscopy, according to a new study. The study, published recently in JAMA (2006; 295:299-305), found that cystoscopy alone identified 91.3% of cancers, whereas the combination of cystoscopy and the NMP22 test (BladderChek, Matritech, Inc., Newton MA) detected 99% of cancers. The test is FDA-approved both as an aid in the initial diagnosis of bladder cancer and for surveil- lance. The fifth most com- mon malignan- cy, bladder cancer comes with a 50% to 90% chance of recur- rence. The resulting need for frequent surveil- lance cystoscopies after the initial tumor resection tends to include supplemental cytol- ...

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Arsenic Ingestion and Bladder Cancer Mortality - What Do the Dose-Response Re Steven H Lamm; Michael B Kruse Human and Ecological Risk Assessment; Apr 2005; 11, 2; Sciences Module pg. 433 Page 2 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Page 3 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Page 4 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Page 5 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Page 6 Reproduced with permission ...

Health Consultation Review of Bladder Cancer Data (May, 2001) Abstract This report is a follow-up to the November 1998 study Cancer Incidence and Birthweight in Relation to Exposure to Raymark Waste. It was undertaken in response to citizens’ concerns about elevated female bladder cancer rates among those who lived closer to Raymark waste. The report re-analyzed data from the original study, taking into account an additional five years of bladder cancer data (1991-1996). New techniques were used to improve statistical precision and more advanced disease mapping methodologies were also employed. The results of this report are therefore believed to be more accurate than the original study. The report found that there were elevated risks for female bladder cancer near Raymark waste sites, but this did not hold true over time. Male bladder cancer was not consistently elevated near Raymark ...

Wipatorn von Heiroth Why he gets bladder cancer again after the treatments? Bladder cancer is the 6 th most common cancer in men and the 9 th in women. Most bladder cancers develop in the lining of the bladder . Bladder cancer begins from one cell, which has genetic change. Due to the genetic changing that cell produces many enzymes, which affect the nearby cells, resulting in the spreading through the lining of the bladder to the muscle or spread to near-by organs and the lymph system. The abnormal cells that are located in the surface of the bladder are called superficial bladder tumour and the ones that penetrate deeper into the muscle are called invasive bladder cancer . Figure shows the developing of the tumour cells. Figure: The development of bladder tumours cells: 1; the abnormal genetic cell 2; cells with more genetic change, ...

14.1. INTRODUCTION AND SUMMARY Table 14.1. Summary of incidence and mortality statistics: bladder cancer INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (invasive, in situ and uncertain) (ICD-O-2 C67) 1997 cases 345 129 474 115 62 177 % of all cancers 3.3% 1.2% 2.2% 2.9% 1.8% 2.3% Incidence and mortality rates (per 100,000 persons per year) crude rate 19.1 7.0 13.0 6.4 3.4 4.9 World age-standardised rate 14.4 4.7 4.2 1.8 European age-standardised rate 22.4 6.7 7.2 2.8 cumulative risk (0-74) 1.6% 0.6% 0.4% 0.2% mortality/incidence ratio 0.333 0.481 0.373 Time trends (all cancers) 1994 cases 353 175 528 115 71 186 ...

For Immediate Release: Contact: Monday March 13, 2006 Mara Radis (410) 203-1970 x12 mradis@candecommunications.com Actor Tate Donovan to Help Bladder Cancer Advocacy Network Shine the Spotlight on Bladder Cancer National Organization Helps Raise Awareness for Disease that Affects 63,000 New Patients on an Annual Basis Bethesda, Maryland – The Bladder Cancer Advocacy Network (BCAN), the first national advocacy organization dedicated to increasing public awareness of bladder cancer announced today that actor Tate Donovan will join the organization as both a national spokesperson and member of the BCAN Board of Directors. Donovan and his family have been profoundly affected by bladder cancer , the Nation’s 5 th most common form of cancer with more than 63,000 new patients diagnosed and 13,000 deaths annually. His father, Dr. Timothy ...

Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer W. Oosterlinck, A. van der Meijden, R. Sylvester, A. Böhle, E. Rintala, E. Solsona Narvón, B. Lobel © European Association of Urology 2006 Page 2 TABLE OF CONTENTS PAGE 1. BACKGROUND 3 1.2 Introduction 3 2. CLASSIFICATION 3 2.1 Histological grading of superficial bladder tumours 3 2.1.1 WHO/ISUP grading 4 2.2 Controversial definition of superficial and infiltrative tumours 4 2.3 Inter- and intra-observer variability in staging and grading 4 2.3.1 Recommendation for use of grading system 4 3. RISK FACTORS 5 4. DIAGNOSIS 5 4.1 Symptoms of TaT1 bladder tumours 5 4.2 Physical examination 5 4.3 Imaging 5 4.3.1 ...

FALL 2005/ WINTER 2006 Predicting Response to Intravesical Therapy for Superficial Bladder Cancer The Genitourinary Cancer Center brings together highly qualified clinical and research faculty and staff committed to eliminating the morbidity and mortality of genitourinary cancers. Each faculty member represents the highest standard of excellence in his/her own field. Working together, we are dedicated to achieving our common Mission. To create a seamless research and clinical care integration that enables the rapid application of research to relevant clinical problems and the immediate translation of scientific discovery to cancer interventions and therapies. Mission • • • AREAS OF intERESt Genitourinary Cancer Center physicians treat the following cancers: ...

Screening for Bladder Cancer C HAPTER 68 By Sarvesh Logsetty Page 2 Screening for Bladder Cancer 68 Prepared by Sarvesh Logsetty, MD 1 I n 1 979 the Canadian Task Force on the Periodic Health Examination addressed the question of screening for bladder cancer in the periodic health examination. The screening tool considered was urine cytology, and it was recommended that the general population not be screened (D Recommendation). The screening of high-risk groups, however, was recommended (B Recommendation) pending further information.< 1 > The current Task Force recommendations for urine screening for microscopic hematuria and urine cytology are a D Recommendation for the general population and a C Recommendation ...

Intravesical EOquin (E09) in theTreatment of Superficial Bladder Cancer JAWitjes,AG van der Heijden Dept Urology,UMCN St Radboud,Nijmegen,the Netherlands Gino Lenaz M.D.,Shanta Chawla M.D. Spectrum Pharmaceuticals,Inc.Irvine,CA 92618 Key words:superficial bladder cancer ;intravesical;Eoquin™ EO9 Abstract EOquin and mitomycin-C (frequently used as intravesical agent in superficial bladder cancer ) are structurally similar but the mechanism of action differs with regard to the ability of oxygen to reverse the activation process and elevated levels of reductases in tumor tissue. Why intravesical application of EOquin?: The bladder is a hypoxic region ;there is a presence of DT-diaphorase enzyme in the bladder ;there is no systemic uptake . In an in vitro experiment we used 4 bladder cancer cell lines that were treated for 60 min.with 0-200 µg/mL MMC or EOquin at 37°C or 43°C.Cell ...

126 INCIDENCE In men it is the fourth most common cancer after prostate, lungs, colorectal malignancy accounting for 6.2% of all cancer cases. In women it is the eighth most common cancer accounting for 2.5% of all cancer cases. Bladder cancer is the second most common urological malignancy after prostate cancer in males. RACE Bladder cancer is roughly two times as common among American white men as among American black men and is only roughly 1.5 times more common among white American than black American women. RATIO The male to female ratio is 3:1. AGE Bladder cancer can occur at any age even in children. It usually occurs in the 4th to 5th decade of life but in the last one decade we often see this malignancy occurring in younger age group also - thanks to rapid industrialization. Younger patients appear to have more favourable ...

134 Carcinoma gall bladder has an unusual geographic distribution. While it is uncommon in Europe and the United States, it is more frequent in Chile, Bolivia and Israel (Orth and Berger, 2000). The incidence of carcinoma gall bladder in India ranges from 1.01 per 100000 for males to 10.1 per 100000 for females (ICMR 1996) but the actual number may be much more in the endemic zones of Western Bihar and Eastern Uttar Pradesh where it is the third commonest malignancy of the alimentary tract (Shukla et. al. 1985). Due to its non specific clinical presentation, it is seldom diagnosed preoperatively except in advanced cases. Survival depends on the ability to achieve a curative resection depending upon the stage of the disease. The overall surgical resection rates range from 10% to 30% only thereby indicating a poor prognosis. The aetiology of carcinoma gall bladder is poorly understood. ...

Bladder Irrigation Treatment for Bladder Cancer Your doctor and you have decided to use medicine to treat your bladder cancer . Bladder irrigation is used to put the medicine into your bladder . Different medications are used for this type of treatment. Your nurse will give you a Patient Education Handout about the medication being used in your treatment. When will I be treated? Before each treatment, your doctor may check a urine sample to see if you have a urinary tract infection. Symptoms of a urinary tract infection may include : C Pain or burning with urination C Back pain C Frequent urinating C Having the urge to urinate, but not being able to C Blood in the urine Report any of these symptoms to a member of your health care team. If there is an infection, your treatment may be postponed. Your doctor will ...

H:\EVERYONE\SYSTEMIC\Chemo\Protocol\GU\GUBP.doc GUBP Interim Version Last revised 1 Sep 1999 Page 1 of 2 BCCA Protocol Summary for Therapy for Locally Advanced Bladder Cancer Using Concurrent Cisplatin with Radiation (Interim Version) Protocol Code : GUBP Tumour Group : Genitourinary Contact Physician : Dr Chris Coppin GU Systemic Therapy Contacts : CCSI Drs Susan Ellard, Judy Sutherland FVCC Dr Chris Coppin VCC Drs Nevin Murray, Cicely Bryce, Kim Chi VICC Drs Heidi Martins, Catherine Fitzgerald ELIGIBILITY/TESTS: Locally-advanced bladder cancer being treated with radical or palliative radiotherapy Calculated creatinine clearance (Cockcroft) > 50 mL/min No contraindication to cisplatin such as clinical deafness TREATMENT: Cisplatin 100 mg/m² q2w x 3 to begin during first week of radiotherapy if possible ...